Pharmacotherapy for uveitis: current management and emerging therapy
- PMID: 25284976
- PMCID: PMC4181632
- DOI: 10.2147/OPTH.S47778
Pharmacotherapy for uveitis: current management and emerging therapy
Abstract
Uveitis, a group of conditions characterized by intraocular inflammation, is a major cause of sight loss in the working population. Most uveitis seen in Western countries is noninfectious and appears to be autoimmune or autoinflammatory in nature, requiring treatment with immunosuppressive and/or anti-inflammatory drugs. In this educational review, we outline the ideal characteristics of drugs for uveitis and review the data to support the use of current and emerging therapies in this context. It is crucial that we continue to develop new therapies for use in uveitis that aim to suppress disease activity, prevent accumulation of damage, and preserve visual function for patients with the minimum possible side effects.
Keywords: clinical trials; immunomodulatory therapeutic agents; immunosuppression; inflammation; uvea.
References
-
- Darrell RW, Wagener HP, Kurland LT. Epidemiology of uveitis. Incidence and prevalence in a small urban community. Arch Ophthalmol. 1962;68:502–514. - PubMed
-
- Goldstein H. The reported demography and causes of blindness throughout the world. Adv Ophthalmol. 1980;40:1–99. - PubMed
-
- Forrester JV. Uveitis: pathogenesis. Lancet. 1991;338(8781):1498–1501. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
